{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:24:36Z","timestamp":1787228676558,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018M641881"],"award-info":[{"award-number":["2018M641881"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010722","name":"Harbin Medical University","doi-asserted-by":"publisher","award":["YJSCX2024-19HYD"],"award-info":[{"award-number":["YJSCX2024-19HYD"]}],"id":[{"id":"10.13039\/100010722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8177130755"],"award-info":[{"award-number":["8177130755"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005046","name":"Heilongjiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["PL2024H119"],"award-info":[{"award-number":["PL2024H119"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102881","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T03:05:31Z","timestamp":1782615931000},"page":"102881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The YAP-TEAD4 inhibitor M511-0965 suppresses triple-negative breast cancer progression by downregulating TGFB2"],"prefix":"10.1016","volume":"71","author":[{"given":"Mengxing","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-5052","authenticated-orcid":false,"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haocheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruipu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofen","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.tranon.2026.102881_bib0001","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.tranon.2026.102881_bib0002","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.tranon.2026.102881_bib0003","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2026.102881_bib0004","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102881_bib0005","first-page":"1481","article-title":"Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers","volume":"27","author":"Choi","year":"2012","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.tranon.2026.102881_bib0006","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the national Cancer institute's surveillance, epidemiology, and end results database","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102881_bib0007","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102881_bib0008","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.tranon.2026.102881_bib0009","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102881_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality","volume":"105","author":"Kerr","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tranon.2026.102881_bib0011","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","article-title":"Therapeutic landscape in mutational triple negative breast cancer","volume":"17","author":"Shi","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2026.102881_bib0012","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.soc.2017.08.004","article-title":"Triple-negative breast cancer: who should receive neoadjuvant chemotherapy?","volume":"27","author":"Chaudhary","year":"2018","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"Suppl 1","key":"10.1016\/j.tranon.2026.102881_bib0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1634\/theoncologist.2011-S1-71","article-title":"Directed therapy of subtypes of triple-negative breast cancer","volume":"16","author":"Carey","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2026.102881_bib0014","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pharmthera.2017.12.011","article-title":"The Hippo pathway in normal development and cancer","volume":"186","author":"Maugeri-Sacc\u00e0","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tranon.2026.102881_bib0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cell.2005.06.007","article-title":"The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the drosophila homolog of YAP","volume":"122","author":"Huang","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102881_bib0016","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.1843810","article-title":"A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP)","volume":"24","author":"Zhao","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.tranon.2026.102881_bib0017","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nature08021","article-title":"Genes that mediate breast cancer metastasis to the brain","volume":"459","author":"Bos","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102881_bib0018","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1101\/gad.233676.113","article-title":"A temporal requirement for Hippo signaling in mammary gland differentiation, growth, and tumorigenesis","volume":"28","author":"Chen","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.tranon.2026.102881_bib0019","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005735","article-title":"Ski regulates Hippo and TAZ signaling to suppress breast cancer progression","volume":"8","author":"Rashidian","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tranon.2026.102881_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ncb3464","article-title":"A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis","volume":"19","author":"Li","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tranon.2026.102881_bib0021","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/onc.2014.5","article-title":"TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells","volume":"34","author":"Bartucci","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.102881_bib0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/CS20201474","article-title":"The Hippo pathway in cancer: YAP\/TAZ and TEAD as therapeutic targets in cancer","volume":"136","author":"Cunningham","year":"2022","journal-title":"Clin. Sci. (London England)"},{"key":"10.1016\/j.tranon.2026.102881_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cbpa.2018.12.007","article-title":"Natural product derived privileged scaffolds in drug discovery","volume":"52","author":"Davison","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.tranon.2026.102881_bib0024","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrd2468","article-title":"Prodrugs: design and clinical applications","volume":"7","author":"Rautio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tranon.2026.102881_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: shifting paradigms in drug discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102881_bib0026","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2174\/1389450117666160101120822","article-title":"Computer aided drug design for multi-target drug design: SAR \/QSAR, molecular docking and pharmacophore methods","volume":"18","author":"Abdolmaleki","year":"2017","journal-title":"Curr. Drug Targets."},{"key":"10.1016\/j.tranon.2026.102881_bib0027","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.4155\/fmc-2013-0123","article-title":"Computational chemistry and computer-aided drug discovery: part II","volume":"8","author":"Bajorath","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.tranon.2026.102881_bib0028","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1007\/s12272-015-0640-5","article-title":"Role of computer-aided drug design in modern drug discovery","volume":"38","author":"Macalino","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.tranon.2026.102881_bib0029","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10522-018-9744-x","article-title":"Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-aided drug discovery study","volume":"19","author":"Mofidifar","year":"2018","journal-title":"Biogerontology"},{"key":"10.1016\/j.tranon.2026.102881_bib0030","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.cell.2008.07.025","article-title":"TGF-beta: a master of all T cell trades","volume":"134","author":"Li","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102881_bib0031","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.2174\/138920111798808347","article-title":"TGF-\u03b22 signaling in high-grade gliomas","volume":"12","author":"Hau","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.tranon.2026.102881_bib0032","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/a-0887-0285","article-title":"Diagnosis and therapy of triple-negative breast Cancer (TNBC) - recommendations for daily routine practice","volume":"79","author":"Schneeweiss","year":"2019","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"10.1016\/j.tranon.2026.102881_bib0033","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2015.12","article-title":"The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications","volume":"17","author":"Maugeri-Sacc\u00e0","year":"2015","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.tranon.2026.102881_bib0034","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-16-3125","article-title":"Exercise-induced catecholamines activate the hippo tumor suppressor pathway to reduce risks of breast Cancer development","volume":"77","author":"Dethlefsen","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102881_bib0035","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/17460441.2019.1604677","article-title":"The compromise of virtual screening and its impact on drug discovery","volume":"14","author":"Slater","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.tranon.2026.102881_bib0036","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-20-0018","article-title":"YAP\/TAZ transcriptional coactivators create therapeutic vulnerability to verteporfin in EGFR-mutant glioblastoma","volume":"27","author":"Vigneswaran","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102881_bib0037","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.tranon.2026.102881_bib0038","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aac5418","article-title":"Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1","volume":"8","author":"Zhang","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.tranon.2026.102881_bib0039","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7150\/ijbs.23230","article-title":"The role of TGF-\u03b2\/SMAD4 signaling in cancer","volume":"14","author":"Zhao","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tranon.2026.102881_bib0040","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.1002\/jcb.28331","article-title":"Role of the transforming growth factor-\u03b2 signaling pathway in the pathogenesis of colorectal cancer","volume":"120","author":"Soleimani","year":"2019","journal-title":"J. Cell Biochem."},{"key":"10.1016\/j.tranon.2026.102881_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102207","article-title":"Smad-dependent pathways in the infarcted and failing heart","volume":"64","author":"Humeres","year":"2022","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.tranon.2026.102881_bib0042","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/92.17.1388","article-title":"Role of transforming growth factor-beta signaling in cancer","volume":"92","author":"de Caestecker","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tranon.2026.102881_bib0043","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1023\/A:1013177011767","article-title":"Malignant cells, directors of the malignant process: role of transforming growth factor-beta","volume":"20","author":"Teicher","year":"2001","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.tranon.2026.102881_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112767","article-title":"TGF-\u03b2-mediated epithelial-mesenchymal transition and cancer metastasis","volume":"20","author":"Hao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102881_bib0045","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-019-1897-5","article-title":"TGF-\u03b2 orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1","volume":"577","author":"Su","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102881_bib0046","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102881_bib0047","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","article-title":"Targeting TGF\u03b2 signal transduction for cancer therapy","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tranon.2026.102881_bib0048","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.1158\/0008-5472.CAN-07-1522","article-title":"Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1","volume":"67","author":"Ehata","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102881_bib0049","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1172\/JCI65745","article-title":"Type III TGF-\u03b2 receptor downregulation generates an immunotolerant tumor microenvironment","volume":"123","author":"Hanks","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2026.102881_bib0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/1878-0261.12162","article-title":"TGF-\u03b2 transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK\/Sp1 signaling pathways","volume":"12","author":"Zhao","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.tranon.2026.102881_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117159","article-title":"Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP","volume":"242","author":"Wang","year":"2020","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.tranon.2026.102881_bib0052","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-008-0125-z","article-title":"Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer","volume":"116","author":"Jansen","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"issue":"41","key":"10.1016\/j.tranon.2026.102881_bib0053","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1038\/onc.2012.515","article-title":"SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation","volume":"32","author":"Buchwald","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.tranon.2026.102881_bib0054","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2828","article-title":"The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression","volume":"13","author":"Chan","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.tranon.2026.102881_bib0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cytogfr.2015.04.002","article-title":"The inducible E3 ubiquitin ligases SIAH1 and SIAH2 perform critical roles in breast and prostate cancers","volume":"26","author":"Knauer","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.tranon.2026.102881_bib0056","doi-asserted-by":"crossref","unstructured":"M. Shah, J.L Stebbins, A. Dewing, J. Qi, M. Pellecchia, Z.A Ronai. Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. Pigment Cell Melanoma Res., 22(6), 799\u2013808.","DOI":"10.1111\/j.1755-148X.2009.00628.x"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:29:58Z","timestamp":1787225398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"alternative-id":["S1936523326002184"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102881","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The YAP-TEAD4 inhibitor M511-0965 suppresses triple-negative breast cancer progression by downregulating TGFB2","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102881"}}